Investigation of current status of pharmaceutical affairs management in 66 healthcare institutions in Haidian district of Beijing
- VernacularTitle:北京市海淀区66家医疗机构药事管理工作现状调查
- Author:
Xianwei KONG
1
,
2
;
Yingying YAN
1
,
2
;
Yinchu CHENG
1
;
Yiheng YANG
1
,
2
Author Information
1. Dept. of Pharmacy，Peking University Third Hospital，Beijing 100191，China
2. Pharmacy Quality Control and Improvement Center of Haidian District，Beijing 100191，China
- Publication Type:Journal Article
- Keywords:
healthcare institutions;
pharmacy affairs management;
on-site inspection;
prescription review;
adverse drug
- From:
China Pharmacy
2025;36(17):2102-2105
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the pharmaceutical affairs management in healthcare institutions from Haidian district of Beijing， and propose countermeasures and suggestions for improving the related work. METHODS The current status of pharmaceutical affairs management in 66 healthcare institutions from Haidian district of Beijing was surveyed through on-site inspections， and the results were statistically analyzed. The inspection items included six special projects： pharmaceutical affairs management and organizational structure of pharmacy departments； drug quality management and control， prescription review， clinical application management of antimicrobial drugs， management of adverse drug events， and management of special drugs. These areas were further divided into a total of 27 specific inspection sub-items. RESULTS & CONCLUSIONS The total proportion of healthcare institutions that fully complied or basically complied with each special project was 90.9%， 97.0%， 86.3%， 90.9%， 90.9%， and 96.9%， respectively. The overall comparison among healthcare institutions that fully or substantially met the standards across medical institutions at different levels showed that the performance of tertiary healthcare institutions was better than that of secondary and primary healthcare institutions. The pharmaceutical affairs management in healthcare institutions within the jurisdiction was proceeding in an orderly manner. There is still room for improvement in further establishing and perfecting the functions of the pharmaceutical affairs management committee， implementing the 2021 Edition of Management Regulations for β -lactam Antimicrobial Skin Tests， enforcing the adverse drug reaction management system， and strengthening the refined management of narcotics and psychotropic drugs.
